Entry Rationale
Given the clear positive news of an upward guidance revision and strong second-quarter performance, entering the position could be considered.
NovoCure surges on guidance raise, Q2 beats
Driven by an upward revision of guidance and strong second-quarter performance, NovoCure's (NVCR) stock price surged.
Given the clear positive news of an upward guidance revision and strong second-quarter performance, entering the position could be considered.
With strong performance and upward guidance momentum, if the target price of $20.0 is reached, I will take profits. If the price fails to hold the support level around $19.37 and drops below the stop-loss price of $18.0, I will cut losses.
A past similar success case is Lockheed Martin (LMT), which rose by 10.5% on July 23, 2026, due to positive earnings guidance news.
Based on the strong materials of an upward guidance and solid Q2 performance, I anticipated a positive trend and aimed for a profit-taking price of $20.0; however, the actual outcome concluded with a disappointing stop-loss of -21.4%. Following a sharp rise to 19.99 on July 23, the price adjustment process began, closing at 17.65 on July 24, which marked the start of giving back the gains. Subsequently, the stock showed a downward trend, falling to the 15 range. Ultimately, it fell below the set stop-loss price of $18.0, confronting the harsh reality of a market where actual performance does not directly translate into stock price stability.
Even if strong news such as robust earnings or upward guidance leads to a short-term surge, it is essential to manage risks more strictly when there is a trend of breaking support levels accompanied by significant volatility in the subsequent candles. In future trades with similar momentum, I will adhere more rigorously to stop-loss criteria when prices rapidly cool after a short-term spike, and I will carefully adjust the approach to chasing purchases during periods of increased volatility.